Status: Recruiting
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
Participants needed: 60
Trial details
Phase: Phase 3Age: 5-17Biological sex: AllType: InterventionalSponsor: AmgenUpdated: Aug 6, 2026Locations: 45
Eligibility criteria
Male or Female participants 5 to < 18 years of age at the time of randomization. [+6]
Arthritis in an HLA-B27-positive male with arthritis onset after 6 years of age [+5]